EVERSANA
↗Chicago, Illinois, USA
EVERSANA is the leading independent provider of global services to the life sciences industry. The company offers a fully integrated commercialization platform designed to solve complex challenges in drug pricing, access, reimbursement, adherence, and product delivery. By combining data-driven insights with a global infrastructure, EVERSANA supports therapies from early-stage clinical development through commercial launch and long-term market optimization.
Formed in 2018 through the merger of several specialized service providers, EVERSANA has rapidly expanded through strategic acquisitions and technology partnerships. The company is known for its 'EVERSANA COMPLETE' model, which provides end-to-end outsourcing for emerging biotechs and established pharma companies alike, effectively acting as a commercialization engine for the industry.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Life Sciences Commercialization Services
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$1B-$5B
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
Total Raised:$1.75B+
Investors:Water Street Healthcare Partners, JLL Partners
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, Cell therapy, Gene therapy, Digital therapeutics, Medical Devices
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:EVERSANA INTOUCH, Waltz Health, Healthware Group, Dohmen Life Science Services, Triplefin, The Access Group
Key Partnerships:Google Cloud (AI Agency development), Oracle (Pharmacovigilance platform), China Resources Pharmaceutical (China market entry), Lyfegen (Value-based contracting)
COMPETITION
Position:Leader
Competitors:IQVIA, Syneos Health, Indegene, Parexel, Avalere Health
LEADERSHIP
Key Executives:
Mark Thierer - CEO
Jim Lang - Board Member (Former CEO)
Greg Skalicky - President & Chief Revenue Officer
Board Members:Jim Lang, Mark Thierer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with EVERSANA. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.